Hypoxia-induced CD137 expression in tumor-infiltrating T lymphocytes is thought to explain why intratumoral injection of agonistic anti-CD137 mAb can achieve immunotherapeutic antitumor effects with minimum systemic side effects (124). Here, TNFRSF9 is linked to neoplasm.